Marcin Zuberek, MD
Urology · Fishers, INNPI 1508397332
Payments from drug & device makers
What this record shows
This record is dominated by other: $22,071 of the $27,820 with a category attached, or 79.3%. Central Indiana URS Consumables, LLC accounts for 79.3% of it on its own, with 34 other manufacturers making up the rest.
Across 146 payments — averaging $190.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Central Indiana URS Consumables, LLC$22K
- Axonics, Inc.$2K
- Medtronic$870
- Sumitomo Pharma America, Inc.$425
- Coloplast$420
- Accord Healthcare, Inc.$279
- plus $2K from 29 others
Across 2 payments — averaging $7800.00 each. An ownership or investment interest held by the physician or an immediate family member.
- Central Indiana URS Consumables, LLC$16K
What the payments were for
- Travel & lodging$1,6416%
- Food & beverage$3,82314%
- Education$2841%
- Other$22,07179%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Central Indiana URS Consumables, LLC | 4 | $22,071 |
| Axonics, Inc. | 13 | $1,576 |
| Medtronic | 10 | $870 |
| Sumitomo Pharma America, Inc. | 17 | $425 |
| Coloplast | 10 | $420 |
| Accord Healthcare, Inc. | 11 | $279 |
| Astellas Pharma US Inc | 7 | $278 |
| Johnson & Johnson | 10 | $275 |
| Procept Biorobotics Corporation | 2 | $173 |
| Pfizer | 6 | $150 |
| Bayer | 7 | $148 |
| Dendreon Pharmaceuticals LLC | 5 | $142 |
| Boston Scientific | 2 | $134 |
| Novartis | 4 | $102 |
| Urogen Pharma, Inc. | 5 | $99 |
| Tolmar, Inc. | 4 | $73 |
| Telix Pharmaceuticals | 2 | $72 |
| AbbVie | 4 | $72 |
| Myriad Genetic Laboratories, Inc. | 3 | $61 |
| Calyxo, Inc. | 2 | $51 |
| Progenics Pharmaceuticals, Inc. | 2 | $38 |
| Halozyme Inc | 2 | $34 |
| Vertex | 2 | $33 |
| Blue Earth Diagnostics | 1 | $25 |
| Merck | 1 | $25 |
| Amgen | 1 | $23 |
| Sun Pharmaceutical Industries Inc. | 1 | $23 |
| Endo Pharmaceuticals Inc. | 1 | $22 |
| Laborie Medical Technologies Corp. | 1 | $22 |
| AstraZeneca | 1 | $20 |
| Hologic Sales And Service, LLC | 1 | $20 |
| Ferring Pharmaceuticals Inc. | 1 | $18 |
| Olympus America Inc. | 1 | $17 |
| Argon Medical Devices, Inc. | 1 | $16 |
| Immunitybio, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Dornier MedTech$88,286
- CVAC Aspiration System$22,071
- Axonics$1,300
- Bulkamid$1,081
- SPEEDICATH$155
- AquaBeam Robotic System$149
- ALTAVIVA$145
- VIRTUE$122
- GENERAL KIDNEY STONE DISEASE$121
How this compares
$27,820 in reported general payments places this provider in the 85th percentile of 272 urology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 41 | $21,432 |
| GemtesaVibegron | 12 | $9,222 |
| Solifenacin Succinate | 80 | $2,279 |
| Tamsulosin Hcl | 281 | $2,257 |
| Estradiol | 28 | $2,081 |
| Finasteride | 105 | $1,285 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 50 | $912 |
| Tolterodine Tartrate ErTolterodine Tartrate | 11 | $859 |
| Oxybutynin Chloride ErOxybutynin Chloride | 50 | $592 |
| Cephalexin | 58 | $485 |
| Testosterone Cypionate | 15 | $375 |
| NitrofurantoinNitrofurantoin Macrocrystal | 22 | $289 |
| Betamethasone Dipropionate | 16 | $273 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 18 | $186 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 13 | $145 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $278 | $21,43241 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $425 | $9,22212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 272 urology providers in Indiana.
Other urology in Fishers
- Benjamin MartinFishers$30K
- Matthew TellmanFishers$26K
- Michael LargeFishers$25K
- Alexander TatemCarmel$418K
- Chad ReichardCarmel$400K
- Michael BorofskyIndianapolis$244K
- Marcelino RiveraIndianapolis$171K
- Matthew MellonCarmel$159K
- James BailenJeffersonville$143K
- Greg SteinbockJeffersonville$134K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.